Best Practice Webinar – Biomarker Testing in Non-Small Cell Lung Cancer

PVI is a payer-centered platform that supports a more consistent, transparent and efficient review of clinical, economic and patient-centered evidence. Watch a demo of the platform.

AMCP's Q3 2026 Precision Medicine Bulletin is now available, featuring a recap of key precision medicine developments from 2026, a review of recent clinical guidelines, highlights from new publications in the field, and updates on AMCP's submission to the National Comprehensive Cancer Network (NCCN).

Pharmacy benefit manager (PBM) reform is evolving rapidly at the state level, creating a complex and often fragmented policy landscape that stakeholders must actively monitor. Understanding which reforms are advancing in each state is critical, as these policies can significantly alter drug pricing dynamics, rebate structures, formulary design, and patient access.